Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients

Clinical Cancer Research

Volumn 18, Issue 11, 2012, Pages 3079-3089

  Spinelli, Elena ^a   Caporale, Roberto ^b   Buchi, Francesca ^a   Masala, Erico ^a   Gozzini, Antonella ^a   Sanna, Alessandro ^a   Sassolini, Francesca ^a   Valencia, Ana ^a   Bosi, Alberto ^a   Santini, Valeria ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD34 ANTIGEN; CD71 ANTIGEN; COMPLEMENT COMPONENT C3B RECEPTOR; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; STAT5 PROTEIN;

AGED; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL SUBPOPULATION; CLINICAL EVALUATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; GRANULOPOIESIS; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; MOLECULAR MODEL; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION;

AGED; APOPTOSIS; BONE MARROW CELLS; CELL PROLIFERATION; ERYTHROPOIETIN; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES;

EID: 84861777979     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0686     Document Type: Article

References (35)

1. van de Loosdrecht AA, Alhan C, Bene MC, Della Porta MG, Drager AM, Feuillard J, et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European Leukemia Net working conference on flow cytometry in myelodysplastic syndromes. Haematologica 2009;94:1124-34.
2. Ogata K, Della Porta MG, Malcovati L, Picone C, Yokose N, Matsuda A, et al. Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. Haematologica 2009;94: 1066-74.
3. Tamura H, Dan K, Yokose N, Iwakiri R, Ohta M, Sakamaki H, et al. Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes. Leuk Res 2010;34:986-90.
4. Cilloni D, Gottardi E, Saglio G. WT1 overexpression in acute myeloid leukemia and myelodysplastic syndromes. Methods Mol Med 2006;125:199-211.
5. Bennett JM. Classification of the myelodysplastic syndromes. Clin Haematol 1986;15:909-23. (Pubitemid 17014716)
6. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88. (Pubitemid 27132124)
7. Greenberg PL. Risk factors and their relationship to prognosis in myelodysplastic syndromes. Leuk Res 1998;22 Suppl 1:S3-6.
8. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-10. (Pubitemid 47315575)
9. Hoefsloot LH, van Amelsvoort MP, Broeders LC, van der Plas DC, van Lom K, Hoogerbrugge H, et al. Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome. Blood 1997;89: 1690-700. (Pubitemid 27097463)
10. Mittelman M, Gardyn J, Carmel M, Malovani H, Barak Y, Nir U. Analysis of the erythropoietin receptor gene in patients with myeloproliferative and myelodysplastic syndromes. Leuk Res 1996;20:459-66. (Pubitemid 26254534)
11. Shimizu R, Komatsu N, Miura Y. Dominant negative effect of a truncated erythropoietin receptor (EPOR-T) on erythropoietin-induced erythroid differentiation: possible involvement of EPOR-T in ineffective erythropoiesis of myelodysplastic syndrome. Exp Hematol 1999;27: 229-33. (Pubitemid 29131733)
12. Fontenay-Roupie M, Bouscary D, Guesnu M, Picard F, Melle J, Lacombe C, et al. Ineffective erythropoiesis in myelodysplastic syndromes: correlation with Fas expression but not with lack of erythropoietin receptor signal transduction. Br J Haematol 1999;106:464-73. (Pubitemid 29450673)
13. Navas TA, Mohindru M, Estes M, Ma JY, Sokol L, Pahanish P, et al. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood 2006;108:4170-7. (Pubitemid 44913289)
14. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009;361:1872-85.
15. Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AD. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 2007;7:118-29. (Pubitemid 46164747)
16. Shaffer LG, Tommerup N, editors. ISCN 2005: an International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S. Karger; 2005.
17. Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, Kamada N. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 1991;77:2031-6.
18. Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud O, Gjertsen BT, et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004;118:217-28. (Pubitemid 38962577)
19. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-25. (Pubitemid 44061337)
20. Westers TM, Alhan C, Chamuleau ME, van der Vorst MJ, Eeltink C, Ossenkoppele GJ, et al. Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. Blood 2010;115: 1779-84.
21. Frisan E, Pawlikowska P, Pierre-Eugene C, Viallon V, Gibault L, Park S, et al. p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes. Haematologica 2010;95:1964-8.
22. Nimer SD. MDS: a stem cell disorder-but what exactly is wrong with the primitive hematopoietic cells in this disease? Hematology Am Soc Hematol Educ Program 2008:43-51.
23. Pellagatti A, Cazzola M, Giagounidis AA, Malcovati L, Porta MG, Killick S, et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood 2006;108:337-345. (Pubitemid 43990647)
24. Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, O'Keefe C, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009;113:1315-25.
25. Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 2010;24:1094-6.
26. Jasek M, Gondek LP, Bejanyan N, Tiu R, Huh J, Theil KS, et al. TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p. Leukemia 2010;24:216-9.
27. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008;451:335-9.
28. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003;120:1037-46. (Pubitemid 36411563)
29. Mundle S, Lefebvre P, Vekeman F, Duh MS, Rastogi R, Moyo V. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophagecolony- stimulating factor in myelodysplastic syndromes using a metaanalysis approach. Cancer 2009;115:706-15.
30. Wells DA, Benesch M, Loken MR, Vallejo C, Myerson D, Leisenring WM, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003;102:394-403. (Pubitemid 36759682)
31. Scott BL, Wells DA, Loken MR, Myerson D, Leisenring WM, Deeg HJ. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood 2008;112:2681-6.
32. Deeg HJ, Jiang PY, Holmberg LA, Scott B, Petersdorf EW, Appelbaum FR. Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flowscores of marrow cells. Leuk Res 2004;28:1177-80. (Pubitemid 39243242)
33. Cortelezzi A, Colombo G, Pellegrini C, Silvestris I, Moronetti Mazzeo L, Bosari S, et al. Bone marrow glycophorin-positive erythroid cells of myelodysplastic patients responding to high-dose rHuEPO therapy have a different gene expression pattern from those of nonresponders. Am J Hematol 2008;83:531-9. (Pubitemid 351874868)
34. Ebert BL, Galili N, Tamayo P, Bosco J, Mak R, Pretz J, et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 2008;5:e35.
35. Pellagatti A, Cazzola M, Giagounidis AA, Perry J, Malcovati L, Della Porta MG, et al. Identification of prognostic markers by gene expression profiling in myelodysplastic syndrome hematopoietic stem cells. Blood (ASH Annual Meeting Abstracts) 2010;116:abs 298.